WOBURN, Mass., July 26 /PRNewswire/ -- “We are pleased to announce our relocation to a larger facility in Woburn, Massachusetts, to support our record growth,” said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. “The move will help to maintain our expansion, particularly in the areas of Research and Development, Customer Service, and Operations.”
CutisPharma offers an easy and time saving solution to compounded prescriptions. FIRST(TM) Unit of Use Compounding Kits provide standardized drug delivery. Pre-measured, pre-weighed components enable pharmacists to dispense prescribed dosage first time, every time. FIRST(TM) products save dispensing time, and increase efficiencies in pharmacy operations. A single NDC number assigned for the entire Kit for each product offers easy third party reimbursement and reduces audit related adjustments. FIRST(TM) Unit-of- Use Prescription Compounding Kits comply with United States Pharmacopeia (USP) Chapter <795>.
CutisPharma currently has nine proprietary prescription compounding kits on the market: five progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, and one Magic Mouthwash kit. Several more compounding kits are in the planning stages.
The FDA estimates that each year in the United States approximately 30 million retail and hospital outpatient prescriptions are prepared through “compounding,” a means by which a pharmacist prepares a customized medication according to a doctor’s prescription to meet an individual patient’s medical need. About 1% of all prescriptions are compounded; and the U.S. market alone for compounding, at the consumer level, represents an estimated $1 billion annually.
About CutisPharma
CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on developing and commercializing value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts, initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 8 million currently compounded prescriptions, by offering FIRST(TM) Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. A U.S. patent has been issued to the Company and additional patents are pending.
For more information please visit our website at www.cutispharma.com
CutisPharma, Inc.
CONTACT: James Nagle, V.P. Business Development of CutisPharma, Inc.,+1-781-935-8141 x120
Web site: http://www.cutispharma.com/